Annoucements - Business
We are pleased to announce the appointment of Ms. Angela Tham as Regional Marketing Manager for Wellesta, Singapore w.e.f. 25th October 2021.
Effective from 25th October 2021

Prior to joining Wellesta, Ms. Angela worked with A. Menarini as a Senior Product Manager. Her marketing experience spans over 8 years of handling both local and regional portfolios in Singapore and across the Southeast Asia region in the pharmaceutical industry in multiple therapeutic areas such as Gynaecology, Obstetrics, Dermatology, Aesthetics, ENT, Urology, Men’s Health & Gastroenterology.

Ms. Angela Tham started her career as a Product Executive for Hyphens Pharma in 2009 and rose to ranks in 2013 as an Assistant Manager role handling market development for 2 years where she started to get involved in the Indonesia Market. With her personal and working experience in both sales and marketing, she started mentoring and supporting both the Singapore team as a Product Manager and the Indonesia sales team in opening new opportunities.

In 2016, she was promoted to Associate Regional Product Manager which expanded her coverage across Hyphens regional offices in Singapore, Malaysia, Indonesia, Philippines and Vietnam focusing on the Dermatology business unit. She is well experienced in handling new product launches, organizing regional symposiums and working on new product developments. She has also been involved in clinical studies conducted across the region, working with various societies and hospital departments.

With her drive to pursue an all-rounded career, Ms. Angela Tham decided to move to A. Menarini Singapore in 2019 as a Senior Product Manager. In her 2 years with Menarini, she was mainly involved in launching 3 new brands including the product development of an anti-aging cosmetic range, working on formulation, branding and packaging design.

Ms. Angela Tham is a science degree graduate majoring in Biomedical Science and Microbiology from the University of Queensland, Australia.

We are very sure that Angela’s experience locally & SEA will help our business growth agenda. Ms. Angela will report to Milan Paleja, Chairman and MD of the Wellesta Group.

We welcome Ms. Angela to the Wellesta family and wish her great success in her new position.
Wellesta Holdings Pte Ltd is pleased to announce a collaboration with Altamira Therapeutics to market and distribute Bentrio in Six Key Asian Markets

Wellesta Holdings Pte Ltd and Altamira Therapeutics Ltd. have signed a letter of understanding (“LOU”) for the marketing and distribution of Bentrio™ in India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam. Bentrio™ is a nasal spray for protection against airborne viruses and allergens. Wellesta will register Bentrio™ in the respective countries and start promoting and selling the product in those markets. In Singapore, Bentrio is classified as a Class A medical device.   

Wellesta Holdings Pte Ltd is a Healthcare Company headquartered in Singapore, and Altamira Therapeutics Ltd. is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. This collaboration will offer greater distribution of Bentrio™ to our consumers in the Asia-Pacific region.  

Bentrio™ is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application in the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. It is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms.  

While talking about this collaboration, Mr. Thomas Meyer, Chairman, CEO and founder of Altamira Therapeutics, said: “Wellesta has achieved rapid growth and great success in building a high-quality portfolio of health care products for distribution in South East Asia and India, and we very much look forward to working with its team.” 

While talking about collaboration, Mr. Milan Paleja, Chairman & MD of Wellesta, said that his company is very excited to partner with Altamira to market Bentrio™, which is already on the market in several big EU countries, to help protect people against airborne viruses and allergens in 6 important countries across Asia. 

  Mr. Paleja also thanked deal advisors, AAA consulting, to help support this transaction.  

About Wellesta Holdings
  
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in Southeast Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in SEA & India as a strategic partner for companies present in these markets and act as a representative for companies that are not present in these markets and would like to sell/market their products in the region.  

Wellesta Holdings operates in a spectrum of business verticals under our Partner Brands and Own Brands including Pharmaceutical, Nutraceuticals, OTC and Medical devices, which is being led by industry-proven leaders at HQ & country level. Wellesta works as an extended arm for principals through win-win partnership and provide superior quality products and services at the right price, by working at full compliance and transparency in our business approach. This joint collaboration supports the mission of Wellesta to provide cost-effective and high-quality products and services and help to deliver better patient outcomes in healthcare.

  
About Altamira Therapeutics  

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: The development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”  

Wellesta Holdings Pte Ltd is pleased to broaden collaboration with Altamira Therapeutics to market and distribute Bentrio in two additional markets

Wellesta Holdings Pte Ltd and Altamira Therapeutics Ltd have broaden their agreement for marketing and distribution of Bentrio™ by including two attractive new markets. In addition to India, Indonesia, Malaysia, Singapore, Taiwan and Vietnam, Wellesta will also start promoting and selling Bentrio™ in Philippines & Morocco, upon registration in these two countries.

Bentrio™ is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application in the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. It is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms.  

Wellesta has successfully registered Bentrio in Malaysia, whilst In Singapore, Bentrio has been classified as a Class A medical device, since the signing of marketing & distribution agreement in October 2021, and is currently in process of obtaining marketing clearance in other six countries covered by the agreement. 

Mr. Milan Paleja, Chairman & MD of Wellesta is excited about extending benefits of Bentrio™ to additional geographies and said “Happy to expand collaboration with Altamira Therapeutics to market and distribute Bentrio™ in Philippines and Morocco as well, which shows great potential for business and further help protect larger masses against airborne viruses and allergens.” 

 
About Wellesta Holdings
  
Wellesta Holdings Pte Ltd is a fast-growing healthcare company headquartered in Singapore with a direct market presence in Southeast Asia, India & North Africa. The company aims to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain.   

Founded in 2019 by two executives with more than 70 years of cumulated experience in leading multinational companies (MNCs) in health care, the company has since grown to more than 540 employees.

Wellesta works with companies to expand their presence in SEA, India & North Africa, as a strategic partner for companies present in these markets and act as a representative for companies that are not present in these markets and would like to sell/market their products in the region.

The company operates in a spectrum of business verticals under Partner Brands and Own Brands including Pharmaceutical, Nutraceuticals, OTC and Medical devices, which is being led by industry-proven leaders at HQ & country level. Wellesta works as an extended arm for principals through win-win partnership and provide superior quality products and services at the right price, by working at full compliance and transparency in our business approach.

About Altamira Therapeutics  

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®, Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol “CYTO.”   

Wellesta Holdings Pte. Ltd. is pleased & excited to announce an update on business development for the Philippines: Wellesta will enter Philippine market through the purchase of a majority stake in Buergli Pharma Inc.
Effective from 1st Nov 2021

Wellesta is a Healthcare company headquartered in Singapore with a direct market presence in South-east Asia, India & North Africa and partnering in MENA. It supports the expansion of healthcare companies with its specialisation in Marketing, Brand Management, Sales & Operations. It also acts as a launchpad for smaller multinational corporations and biotech companies to venture into the Asia-Pacific region. Wellesta’s key focus areas are Pharmaceuticals, Nutraceuticals, OTC and Medical devices and to support our principals’ products at each stage of product life cycle.

Wellesta aims to be a valued partner to healthcare companies serving the community with a cost-effective & expanded access product portfolio. Wellesta is led by industry-proven leaders at HQ & in each country, where it is currently present.

Buergli Pharma Inc. has been operating in Philippines as an established Healthcare company for 15 years and is also committed to providing affordable quality medicine and unique products to further develop and improve healthcare outcomes in the Philippines and Southeast Asia. The company’s strong leadership brings together seasoned pharmaceutical, OTC, and healthcare marketing professionals with relevant perspectives and strong, solid ties to the healthcare industry in the Philippines.

This new company will be named Wellesta Buergli Pharma Inc. This partnership will facilitate Wellesta’s entry into the Philippines’s market, launch current in-licensed products in Philippines as well as own brands. Wellesta’s wider product range & larger geographic presence will also help Buergli to strengthen its current portfolio. This will lead to win win partnership for both companies.

Ms. Carla Aquino has been appointed as Country Head of Wellesta Buergli & will lead the business for Philippines. The announcement of Carla was made earlier on October 19th, 2021.

With the new combined business, we are confident of more employment in country and more development opportunities to current employees. This will lead to larger and faster growing business for our current employees & partners in Philippines.

We thank all who supported us in this transaction!

Milan Paleja
Chairman & MD, Wellesta
Reiner Gloor
President, Buergli Pharma
We are pleased to announce an update on business development for the Malaysian market: Wellesta group in Malaysia will be merging business with the TrueLife group in Malaysia.
Effective from 6th Jan 2021

We are pleased to announce an update on business development for the Malaysian market: Wellesta group in Malaysia will be merging business with the TrueLife group of Malaysia. The nutraceutical business will be done by Wellesta TrueLife Sdn. Bhd. and the pharma business will be done by Wellesta Healthcare Sdn. Bhd.

Wellesta is a company headquartered in Singapore which supports the expansion of healthcare companies with its speciality in Marketing, Brand Management, and Sales & Operations. It also acts as a launchpad for smaller multinational corporations and biotechnological companies to venture into Asia-Pacific. Being led by industry-proven leaders, Wellesta aims to be a valued partner to healthcare companies serving the community in Asia-Pacific with cost-effective and extensive pharmaceutical and healthcare products. TrueLifeSciences is an established Malaysian company committed to producing supplements of the finest quality with its innovative “Nutraceutical” range of products. With the company’s core strength in innovation, technology and regulatory expertise, the company is focused on addressing the various needs for disease prevention and treatment. TrueLifeScience’s mission is to empower and enrich lives by educating and providing high quality health care products for the betterment of individuals.

The merger of the two companies in Malaysia accelerates business development for Wellesta into the Malaysian market and similarly strengthens opportunities for TrueLifeSciences to venture into Asia-Pacific and other countries where Wellesta operates directly and through partners. Additionally, the comprehensive technological and communication structure of TrueLifeSciences supports Wellesta to draw further customer and business networks. This merger aims to leverage on the opportunity to increase employment in the market through such difficult times. It will hence be a union of the two companies to collaborate and achieve their similar goals.

Both Wellesta and TrueLifeSciences focus on both the individual and the patients' well-being. With this, Wellesta TrueLife’s mission to serve the people by providing quality and accessible healthcare products and services at an optimum price will be achieved through this merger, which will be driven by our commitment, in-market expertise, and efficient enactment.

We are pleased to announce the appointment of Ms. Carla Aquino as Country Manager for Philippines for Wellesta w.e.f 18th October, 2021.
Effective from 18th Oct 2021

Prior to joining Wellesta, Carla was with AstraZeneca Philippines as Business Unit Head and Head for the Oncology Business Unit. She has extensive experience with almost 19 years in the pharmaceutical industry, both in consumer and ethical businesses, handling multiple therapeutic areas such as Cardiovascular, Diabetes, Neurology, Psychiatry, Respiratory and Oncology.

Ms. Carla Aquino started her career as Territory Manager/Product Specialist for Roche Philippines, then moved on from sales to marketing both in the OTC and Oncology businesses. During her 10 years in Roche, she had regional assignment in Roche Hong Kong Ltd. After Roche, she moved to GSK as Senior Product Manager for the CNS Portfolio. As she continued to take on bigger roles, she moved to Boehringer Ingelheim (BI) as Head of Specialty Business Unit. In BI, she handled Oncology and Neurology while being the lead for market access and commercial excellence initiatives. She played an integral role in launching and growing the Specialty Business of BI.

Ms. Carla then moved to AstraZeneca as the Business Unit Head for the Oncology Business Unit, where she was part of the Country Leadership Team. She had led the team in coming up with various patient ecosystem solutions which gained various awards both in AstraZeneca and externally, including multiple stakeholder partnerships on early cancer diagnosis, artificial intelligence, and other patient programs. She has rich experience on areas of talent development, high performance culture, process simplifications, pilots, and innovations. She holds a degree in BS Management Major in Communications Technology and an MBA from the Ateneo de Manila University.

We at Wellesta see good growth opportunities in the Philippines Pharmaceutical & Nutraceutical Markets. We are sure that Ms. Carla Aquino’s experience and leadership will help achieve our vision and mission in the Philippines. Ms. Carla Aquino will report to Milan Paleja, Chairman and MD of the Wellesta Group.

We welcome Ms. Carla to Wellesta family and wish her all success & joy in her new position.
We are pleased to announce the appointment of Ms. Prinka Mittal as Business Development & Marketing Manager for Wellesta Holdings, Singapore & her appointment is w.e.f. 16th August 2022.
Effective from 16th Aug 2022

Prior to joining Wellesta, Ms. Prinka worked with Naari Pharma (a Tenshi Group of Lifesciences’ company) as Senior Manager, Business Development for other regulated markets, emerging markets and global strategic accounts. Her career spans over 10 years of comprehensive experience in International Business Development for regulated markets like Europe, Australia & NZ, Canada and emerging markets. Ms. Prinka has handled multiple roles in her previous assignments including project management, portfolio designing and leading key launches in various markets under the larger role of business development.

She started her career from Strides Pharma as an executive in business development for domestic division and moved on to international business development in subsequent roles. She has also worked for a brief period at Biocon Ltd. as an International Marketing Executive for API Division - APAC and South Africa markets.

Ms. Prinka Mittal pursued her B.Pharm and MBA from Narsee Monjee Institute of Management Studies (NMIMS) Mumbai.

We are sure that Ms Mittal's rich experience and leadership will support us achieve our vision and mission. She will report to Milan Paleja, Chairman and MD of the Wellesta Group.

We welcome Ms. Prinka Mittal to the Wellesta family and wish her great success.
We are pleased to announce the appointment of Mr. Ravinder Kumar Sagar as CEO and Country Head for India with effect from Feb 1st 2021.
Effective from 1st Feb 2021

Mr. Ravinder Kumar Sagar has been appointed as CEO and Country Head of India with effect from Feb 1st 2021. Mr. Sagar is a seasoned business leader with 39 years of experience, and an ambitious visionary who believes in looking at problems as opportunities. He was previously associated with Novartis for over three decades.

His experience spans over the entire country and has led businesses in specialties like Transplant & Immunology, Oncology, Established brands business, Respiratory and most recently with Key Accounts Management, which cuts across all the businesses of the organization.

He started his career as a Medical Representative and rose to rank as Area Manager, Regional Manager, Business Head, and also a member of the Pharma Executive Committee in his journey with Novartis. He managed Sales, Marketing, Sales-Force Effectiveness, FF deployment project post-merger in Novartis, Third-party FF, and Key Accounts Management. KAM became the benchmark for not only Indian Pharma but also in the AMEA (Asia, Middle East, Africa) region. He was the first-time recipient of the "Manager of the Year" award in 2018, which was awarded by the regional head. Mr. Sagar completed his MSc in Life Sciences from Panjabi University Patiala and Masters in Marketing Management from NMIMS Mumbai.

We at Wellesta see good opportunities in Indian Healthcare Market, as well as ventures for Wellesta to grow and make strong progress. We are sure that Mr. Sagar's experience and leadership will help guide our India business plan to achieve our vision and missions in India. Mr. Sagar will report to Milan Paleja, Director of Wellesta Healthcare India, and also the Chairman and MD of the Wellesta Group.

We wish Mr. Ravinder Kumar Sagar great success in this new position.
We are pleased to announce the appointment of Mr. Ravinder Kumar Sagar as Senior Advisor to India Leadership Team for India Business.
Effective from 15th Jul 2020

We are pleased to announce that Mr. Ravinder Kumar Sagar has been appointed as Senior Advisor to India Leadership Team with effect from 15th July, 2020. Mr Sagar is a seasoned business leader with 39 years of experience and a visionary who believes in looking at problems as opportunities and always aiming for slightly impossible objectives. He was previously associated with Novartis for over 3 decades.

His experience spans over entire country and has lead businesses like Transplant & Immunology, Oncology, Established brands business, Respiratory and more recently with Key Accounts Management which cuts across all the businesses of the organization

His career started as Medical Rep, rose in to rank as Area Manager, Regional Manager, Business Head and member of Pharma Executive Committee in his 3 decades journey with Novartis. He managed Sales, Marketing, SFE (Sales Force Effectiveness), FF deployment project post- merger in Novartis, Third party FF and Key accounts management. KAM became the benchmark for not only Indian Pharma but also in the AMEA region. He was awarded “Manager of the year in 2018” by the regional head which was awarded for the first time to any individual in the past.

Mr. Sagar completed his MSc in Life Sciences from Panjabi University Patiala and Masters in Marketing Management from NMIMS Mumbai.

We at Wellesta are very optimistic about opportunities in Indian Healthcare Market & opportunities for Wellesta to grow & make strong progress. We are sure that Mr. Sagar's experience & leadership will help our India Business plan to achieve our Vision & Mission in India.

Mr. Sagar will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman &MD of the Wellesta Group.

We welcome Mr. Ravi Kumar Sagar to our Wellesta family and wish him great success in this role.
We are pleased to announce our Strategic Business Alliance in India with Parazelsus through its subsidiary company Wellesta Healthcare Pvt. Ltd, India.
Effective from July, 2020

Wellesta Holdings Pte. Ltd is pleased to announce strategic alliance in India with Parazelsus through its subsidiary company in India, Wellesta Healthcare Pvt. Ltd.

Parazelsus is an MNC company founded by Peter Zuellig in 2007 and operates in multiple countries including India, specializing in Distribution & Logistics. The Company is led by Markus Haefeli as Managing Director. Parazelsus India with its focus on Distribution and Logistics in the Healthcare sector, decided to partner with Wellesta in India for its CSO & Sales and Marketing business.

Wellesta’s core strength is Marketing, Brand Management, Sales & Operations with world class standards in its business approach and compliance. We foresee this partnership will make a Perfect Fit by offering an end-to-end business solution to business partners. With this decision 120 employees have moved from Parazelsus to Wellesta in India.

This will help us achieve our goal to provide high quality end to end professional services and support while providing high quality healthcare products at optimum prices, to support improving health for patients. Our focus would be driven through our dedicated efforts, strong in-market experience, determination and commitment.
We are pleased to announce the appointment of Mr. Kamal Anand as Director, Sales for Wellesta Healthcare Pvt. Ltd, India.
Effective from 1st Dec 2019

Mr. Kamal Anand has been appointed Director, Sales for India business with effect from 1st December, 2019. Mr. Anand is a competent professional with over 35 years of experience in Strategic Planning, Sales & Marketing and Business Development. In his last role, he was BU Head, Consumer Products Divison at Plethico Pharmaceuticals Ltd.

He possesses a strong leadership record and has a deep understanding of the consumer and business landscape across geographies having worked in the FMCG and Healthcare sector both in India and abroad. He started his career after his MBA as a Management Trainee in Ranbaxy, and later worked in DFM Foods, Dabur, Novartis and Plethico.

Mr. Anand holds an undergraduate and post graduate degree in Life Sciences as well as LLB degree from Delhi University and an MBA from Jodhpur University.

We at Wellesta are very optimistic about the opportunities in Indian Healthcare Market & opportunities for Wellesta to grow & make strong progress. We are sure that Mr. Anand's rich experience & leadership will help us to achieve our Vision & Mission in India.

Mr. Anand will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of the Wellesta Group.

We welcome Mr. Kamal Anand, who is originally from Delhi and is now based in Mumbai, to our Wellesta family. He will lead Sales Organisation & be a part of India Leadership team.
We are pleased to announce the appointment of Mr. Sharad Virmani as Director, Partner Business for Wellesta Healthcare Pvt. Ltd.
Effective from 1st Feb 2020

Mr. Sharad Virmani has been appointed as Director, Partner Business for Wellesta Healthcare Pvt. Ltd with effect from 1st February, 2020. Mr. Virmani is a very well-rounded professional with over 35 years of experience in Pharma, Capital Equipment, Medical Devices, Diagnostics, Surgical & Healthcare in MNC & Indian Companies. In his last role, he was Country Head and Business Director - South Asia for Sales, Marketing & Contract Sales Operations at Parazelsus Pte Ltd.

His experience in business spans over Pan-India, Bangladesh and Nepal for both MNC’s and Indian Companies. It encompasses of setting up and managing Contract Sales Operations & New Business Divisions with exposure to handling multiple therapeutic segments.

His career started as a Medical Representative at Serdia and Hoechst (Sanofi) and later worked with Torrent, AstraZeneca, Nicholas Piramal, Micro – BAL, Pharmalink (Invida), Comed and Parazelsus.

Mr. Virmani is a Science Graduate from Kanpur University and has a Diploma in Export Management from Indian Institute of Export Management.

We at Wellesta are very optimistic about opportunities in the Indian Healthcare Market & opportunities for Wellesta to grow and make strong progress. We are sure that Mr. Virmani's rounded experience & leadership will help to achieve our Vision & Mission in India.

Mr. Virmani will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of the Wellesta Group.

We welcome Mr. Sharad Virmani, originally from Delhi who is now based in Mumbai, to our Wellesta family and we look forward for him to make our company reach greater heights with his contribution.
Wellesta & Rubicon Research announce partnership to launch Nicotine Mini Lozenges in Asia.

Rubicon Research Pvt Ltd and Wellesta Holdings Pte. Ltd enter into a licensing and supply partnership to launch a highly effective nicotine lozenge that helps smokers to quit smoking. This smoking cessation product helps smokers successfully wean off their nicotine addiction in 12 weeks and helps them embark on a healthier journey of living cigarette-free.

Wellesta Holdings Pte. Ltd is a Healthcare Company headquartered in Singapore and Rubicon Research is an Intellectual Property led Pharmaceutical Company based out of India, the US and Canada. This partnership will offer an effective smoking cessation product to our consumers in Asia.

The Nicotine Mini Lozenges are part of a 12-week therapy program, helping smokers gradually adjust to having less nicotine till they no longer need any. The lozenges help relieve nicotine cravings and alleviate withdrawal symptoms. The sugar-free lozenges are available in two strengths—2 mg and 4 mg—and come in a pack of 20 lozenges in 3 exciting flavors - Cherry, Cinnamon & Mint. Product will be sold in Wellesta Brand name.

While talking about this unique product, Mr. Milan Paleja, Chairman and Managing Director of Wellesta, said “With this collaboration we aim to help smokers quit the habit of Smoking and live healthier life. We will launch this smoking cessation product in Singapore, Indonesia, Malaysia, Philippines and Thailand and it will be sold under a Wellesta brand.”

Talking about the partnership, Parag Sancheti, Chief Executive Officer, Rubicon Research, said, “We are excited to partner with Wellesta Holdings for the promotion and distribution of our products in the Asia Pacific region. Finding the right partner who is aligned with our vision and core values is important for us. Through this partnership we can leverage Wellesta’s powerful sales, marketing, and distribution networks to provide an innovative product that helps people take charge of their health.”

About Wellesta Holdings
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in South-east Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in SEA & India as strategic partner for companies present in these markets and acts as a representative for companies that are not present in these markets and would like to sell/market their products in the region. 

Wellesta Holdings operates in a spectrum of business verticals under our Partner Brands and Own Brands, including Pharmaceutical, Nutraceuticals, OTC and Medical devices. Being led by industry- proven leaders at HQ & country level. Wellesta works on extended arm for principals through win- win partnership and provide superior quality products and services at right price, by working at full compliance and transparency in business approach.  This joint venture supports the mission of Wellesta to provide cost-effective and high-quality products and services and help to deliver better patient outcomes in healthcare.

About Rubicon Research Pvt Ltd
Rubicon Research is an IP led, specialty pharmaceutical company that develops, manufactures and commercializes its value-added formulations for the global market. The company leverages its proprietary technologies and specialized formulation development skills to provide solutions to complex delivery challenges, enabling better patient outcomes.

Rubicon Research holds more than 50 issued patents in drug delivery technologies and its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, ophthalmic, injectable, sterile, topical, drug device combinations, and fixed-dose combinations. Its flagship manufacturing facility has been inspected by leading global health authorities, including the US FDA and UK MHRA.

Rubicon Research is a portfolio company of General Atlantic, a global growth equity investor with nearly USD 35 billion in assets under management.

For additional information, please visit Rubicon or LinkedIn, Facebook , Twitter.
We are pleased to announce the appointment of Mr. Dinesh Nair as Director, Supply Chain for India Business.
Effective from 1st Dec 2019

Mr. Dinesh Nair has been appointed as Director, Supply Chain for Wellesta Healthcare Pvt. Ltd with effect from 1st December, 2019. Mr. Nair is a seasoned business leader with over 35 years of experience in Pharmaceutical, OTC, Medical Nutrition & Food Industry locally & internationally. He was previously Managing Partner at Integratos India LLP, India.

His experience in business spans over Asia Pacific and Africa for both MNC’s and Indian Companies. It encompasses the setting-up of new businesses, opening-up new Emerging markets, turning around under-performing businesses, establishing sales & distribution networks, managing P & L and leading cross-cultural & cross- functional teams across geographies.

His career started as Distribution Manger at Themis Pharmaceuticals and Medley Pharma later worked at First Arabian department stores, Novartis, Nestle, Equant Consultants Pvt. Ltd and Integratos India LLP.

Mr. Nair completed his post graduate diploma in Marketing & Sales Management and Computer Applications. He has obtained a Bachelor degree in Science from Mumbai University, India.

We at Wellesta are very optimistic about opportunities in Indian Healthcare Market & opportunities for Wellesta to grow & make strong progress. We are sure that Mr. Nair's experience & leadership will help to achieve our Vision & Mission in India.

Mr. Nair will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of the Wellesta Group.

We welcome Mr. Dinesh Nair, a Keralite who is now based in Mumbai, to our Wellesta family and wish him great success in his future endeavours.
We are pleased to announce the appointment of Mr. Partha Dutt as Director, Marketing & New Product Strategy for India business.
Effective from 1st Mar 2020

Mr. Partha Dutt has been appointed as Director, Marketing & New Product Strategy for Wellesta Healthcare Pvt. Ltd with effect from March, 2020. Mr. Dutt is a competent professional with over 22 years of experience in Consumer Healthcare, OTC and FMCG (Health & Wellness). In his previous role as CEO of Nutrite Healthcare, he was responsible for setting up the nutraceutical business from scratch.

He comes with extensive knowledge in various categories and experience in strategic and operational front. His strength lies in his ability of working collaboratively with cross-functional teams, taking high levels of ownership and adding value to their decision-making.

Mr. Dutt has been in various leadership roles across leading companies like 3M, VLCC, GSK and Novartis. His experience spans across various categories like VMS, cough/cold/fever, pain and inflammation, nutritional supplements, wound care etc. Mr. Dutt holds a MMS (Marketing)- Business Management and B.Pharm degree from Mumbai University.

We at Wellesta are very optimistic about the opportunities in Indian Healthcare Market & opportunities for Wellesta to grow & make strong progress. We are sure that the addition of Mr Partha Dutt to team will help us to achieve our Vision & Mission in India.

Mr. Dutt will report to Milan Paleja, Director of Wellesta Healthcare India & also Chairman & MD of the Wellesta Group.

We welcome Mr. Partha Dutt, who is originally from Kolkata and now based in Mumbai to lead Wellesta India's Marketing & New Product Strategy with his expertise and strategic prowess.
We are pleased to announce the appointment of Mr. Paul Lim as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia.
Effective from 1st Mar 2020

Mr. Paul Lim has been appointed as Country Head for Singapore and OTC Lead for Singapore, Malaysia and Indonesia with effect from 1st March, 2020.

Mr. Lim previously worked at Church & Dwight where he launched and achieved market leadership in numerous countries in the Nasal care and VMS categories as OTC Lead - Asia Pacific. Mr. Lim is a highly motivated and experienced commercial leader with over 18 years of experience in the pharmaceutical and consumer health industry across Asia Pacific.

With his expertise and robust experience, he has held various key commercial roles in multinational companies such as Pfizer, Alcon and Church & Dwight. He also enabled Alcon Singapore to extend its leadership in the pharmaceutical franchise of ophthalmology as Business Unit Head.

He holds Bachelor of Business degree from the University of Central Queensland and has completed his coursework for Global MBA from University of London.

We at Wellesta see good opportunity for Singapore Pharma & OTC Market and in other SE emerging markets. With addition of Mr. Lim to Wellesta team, would help driving opportunities and meet the Vision and Mission of our company.

Mr. Lim will report to Milan Paleja, Director of Wellesta Healthcare Singapore Pte Ltd & also Chairman & MD of Wellesta Group.

We welcome Mr. Paul Lim, who is now based in Singapore, to our Wellesta family. We look forward for his dedicated contribution in the overall management and growth of Wellesta business in Singapore as well as being the Lead for the OTC Businesses in Malaysia and Indonesia.
We are pleased to announce the appointment of Ms. Sally Kuah as Country Manager for Malaysia for our Pharma business w.e.f 1st July, 2021.
Effective from 1st July 2021

Ms. Sally Kuah has been appointed as Country Manager for Wellesta Healthcare Sdn Bhd, Malaysia. This legal entity will focus on Pharmaceutical Business of Wellesta in Malaysia. Sally will join us from 1st July 2021.

Her last position was the Business Unit Director for MSD Malaysia, Singapore and Brunei. She has extensive experience with 20 years in pharmaceutical industry in multiple therapeutic areas such as Vaccine, Neurology, Psychiatry, Diabetes, Ophthalmology and Cardiovascular.

Ms. Sally Kuah started her career as Product Specialist for Sanofi Pasteur and moved to marketing role after 2 years. During her stint in Sanofi Pasteur, she managed both the paediatric and adults/traveller’s vaccines. After Sanofi, she moved to Novartis as the Product Manager and continued to take on bigger roles over the years as Sales and Marketing Manager and Franchise Head. In Novartis, she handled multiple portfolios from neurosciences, ophthalmology, heart failure cardiovascular and diabetes. She also played an integral role to merge the Alcon and Novartis ophthalmology portfolios and successfully led the entire team as a combined unit.

Ms. Sally Kuah moved to MSD as the Business Unit Director for the Primary Care Business, with expanded responsibilities covering 3 countries. She has experience as a member of the Country Leadership Team for more than 8 years. She has led multiple country-initiated projects which touched on people and transforming work cultures, process simplifications, pilots and innovations.

She is a science degree graduate in Biotechnology (first class honors) from Universiti Putra Malaysia and holds an MBA from Charles Sturt University, Australia.

We at Wellesta see good opportunities in Malaysian Pharmaceutical & Nutraceutical Markets. We see a strong growth opportunity in both segments. We are sure that Ms. Sally Kuah’s experience and leadership will help our Malaysia business plan for Pharma business to achieve our vision and mission in Malaysia.Our Nutraceutical, Direct to Consumer Business in Malaysia will be under Wellesta Truelife Sdn. Bhd. entity which is led by Mr. Joe Pramesh Ganesaguru.

Both Ms. Sally Kuah & Mr. Joe P will report to Milan Paleja, Chairman and MD of the Wellesta Group.

We welcome Ms. Sally to Wellesta family and wish her all success & joy in her new position.
We are pleased to announce the appointment of Mr. Vishwajit Kamat as Chief Commercial Officer for Wellesta India and Gynaec Business Lead for Wellesta Group of Companies.
Effective from 20th June 2022

Mr. Vishwajit Kamat has been appointed as Chief Commercial Officer for Wellesta India and Gynaec Business Lead for Wellesta Group of Companies with effect from June 20th 2022. Mr. Kamat is a seasoned Business leader with over 39 years of experience in the pharmaceutical industry in different responsibilities across the sales, marketing & operational value chain. In his last role , he was SVP & Cluster Head with Zydus Cadila, India.

His journey started with Cipla and he was associated with other firms like Mylan, UCB, Johnson & Johnson, Bayer Zydus Pharma, and German Remedies (Zydus Group). These assignments have enabled distinguished perspective and exposure to varied business models and a plethora of therapeutic segments. In his previous assignments, he has successfully launched business units with Aristo (Otsira Genetica), German Remedies, Zydus (Evona), and Mylan.

He has built & nurtured values while creating cohesive winning teams for driving business and ensuring their career growth. He has built businesses adhering to global compliance standards, thereby bringing sustainability and adaptability to enduring profitability.

Mr. Kamat holds a graduate degree in science from Dharwad University, Karnataka and he has pursued studies in management with two degrees from reputed institutes - Masters in Marketing Management from NMIMS, Mumbai University and Executive MBA - General management from IIM Ahmedabad. He is actively engaged as visiting faculty, keynote speaker and guest lecturer with management institutions of repute like the NMIMS University, Welingkar School of Management Studies, Xavier’s Institute of Management & Research in Mumbai. It remains a key aspect in his learning curve to share his thoughts and learn from the newness and disruption created by younger minds.

He will be responsible to lead Commercial Organisation for Wellesta India organisation and will report to Wellesta India CEO, Ravi Sagar. He shall also lead Gynaec franchise across Wellesta Group companies for which he will report to Mr. Milan Paleja, Chairman & MD of Wellesta Group. We are sure that Mr. Kamat’s experience and leadership will help and support our India business plan to achieve our Vision and Mission. We welcome Mr. Vishwajit Kamat to Wellesta family and wish him great success in this new position.

We are pleased to announce the appointment of Mr. Yohannes Sinaga as Country Manager, PT Wellesta CPI Indonesia.
Effective from 1st May 2020

Mr. Yohannes Sinaga has been appointed as the Country Manager for PT Wellesta CPI Indonesia, effective from 1st May 2020.

His last position was Chief Marketing Officer for AstraZeneca Indonesia. He has extensive experience with 15 years in pharmaceutical industry.

Mr. Sinaga has experience in various positions including sales and marketing, as well as various experiences in varied therapeutic areas. He has extensive engagement with Medical Association Groups including the association of Pediatrician, Psychiatry, Internal Medicine, Hematology – Oncology, Surgical Oncology, Pathology, Pulmonology, Hepatology, Nephrology, Virology, Neurology, Rheumatology, Urology, Gynecology, as well as with Government Stakeholders.

Mr. Sinaga’s career started as Product Specialist for Novartis in 2006, then moved to marketing role as a Product Manager, he worked with Novartis for 5 years. In 2011, he decided to move to Roche Indonesia as an Oncology Product Manager, 1 year later was promoted as a Group Product Manager and later was appointed as Business Unit Head. He joined AstraZeneca (AZ) in 2016 as a Business Unit Director for Respiratory Disease as well as to leading Core Products and later to lead the Learning & Development Department. Mr. Sinaga was a member of AstraZeneca International Marketing Excellence Champion with the role to set Respiratory strategy plan to countries in international region.

Mr. Sinaga holds MBA from IPMI International Business School in Jakarta as well as a Certified Pharmacist/Apothecary from University of Padjadjaran Bandung – Indonesia.

We at Wellesta are very optimistic about Indonesian Healthcare Market & opportunities for Wellesta to progress. We are sure that with Mr. Sinaga’s leadership the Indonesia team will help achieve our Vision & Mission. Mr. Sinaga will report to Milan Paleja, Director of PT Wellesta CPI Healthcare & also Chairman & MD of Wellesta Group.

We welcome Mr. Yohannes Sinaga to Wellesta family and wish him great success in his new position.
We are pleased to announce a Supply and Licensing collaboration with SGN Nanopharma, Inc. and Cureleads to launch Nanotherapeutics Optha in SEA and MENA
Effective from 27 Apr 2021

This collaboration aims to establish a series of nanotherapeutics technology for patients with dry eye diseases. The first product to be launched will be in the Ophthalmic category.

SGN Nanopharma, Inc. is an innovative, clinical-stage, and revenue-generating developer of nanotherapeutics. Cureleads is a Dubai/Beirut-based pharmaceutical company, with a market presence in MENA, that aspires to transform patient’s lives by leading the path to cure. This landmark partnership is a major stride to fulfill the needs in large, growing therapeutic categories, which helps our patients achieve better outcomes through high-quality healthcare products.

Talking about this collaboration, Dr. Navdeep Jaikaria, Founder, Chairman, and CEO of SGN Nanopharma, Inc., said, "We are very excited about this partnership. We plan to bring multiple products to these growing and emerging markets of Asia and MENA through our partners, Wellesta and Cureleads."

Mohamad Rammal, CEO of Cureleads, said, "We are excited to bring nanotherapeutics technology for patients with dry eye disease across MENA. This collaboration with SGN Nanopharma will have a huge impact on patients in the MENA region."

Mr. Milan Paleja, Chairman and Managing Director of Wellesta, shared, "We are excited to bring enhanced technology products for our patients in Asia and MENA. This will help our dry-eye patients achieve much better results, compared to currently available products in the market. This collaboration with SGN Nanopharma and Cureleads is a big step towards getting higher efficiency products for our patients in Asia and MENA."
We are pleased to announce our Strategic Business Partnership for Middle East & North Africa with Cureleads, a company headquartered in Dubai & Beirut.
Effective from 9 Sep 2020

We are pleased to announce the collaboration of Wellesta and Cureleads.

Wellesta is a company headquartered in Singapore and support Healthcare companies to expand their reach of products for larger access to patients & brand building by way of offering sales, marketing & distribution. It also helps smaller MNC’s & Biotech companies as launch pad for their products to be launched in Asia Pacific. Wellesta is led by Industry Proven leaders at HQ & Country level.

Cureleads is a company headquartered in Dubai & Beirut and aspires to transform patient’s lives by leading the path to cure specialty and rare diseases. It is founded by highly profiled industry leaders regionally and globally.

Cureleads is involved in the business of distribution and marketing of medicinal and pharmaceutical products in Middle East, Dubai & North Africa.

Wellesta is in the business of marketing, brand creation, sales & distribution of medicinal and Healthcare products with focus on Asia Pacific.

With this collaboration both companies can help companies to get coverage across Asia Middle East & Africa (AMEA) geographies. Both companies operate on the principles of High Integrity, Value added partner & Full transparency for our Principals. This alliance will help companies get a partner which provides excellent reach in AMEA countries.

Apart from this, both companies will also provide bilateral support for each other through medical talks, health fairs, newsletters and websites or such other media. They will carry out joint research on the demographics, risk profiles and care needs of the population in both territories from time to time.

Thus, Wellesta’s goal to support and provide high quality healthcare products & services at optimum price to improve health access to masses, and Curelead’s goal to lead the transformation of patients’ lives & curing speciality diseases will be accomplished through this collaboration in Asia Middle East & Africa. Our focus would be driven through our dedicated efforts, strong in-market experience, best-in class capabilities, determination and excellent execution.
We are pleased to announce partnership in Indonesia by acquiring majority of shares & management control of PT Citra Pharma Indonesia.
Acquired from 1st Dec 2019

We are very pleased to announce our partnership in Indonesia by acquiring majority of shares & management control of PT Citra Pharma Indonesia from current shareholders. It will now operate under the new name PT Wellesta CPI Healthcare and will be based from Jakarta. PT Citra Pharma Indonesia is in successful operations for last 12-years and have been partner with MNC players in Pharma and Healthcare sector in the Indonesian market. PT Citra Pharma provides medical sales & marketing services to MNC in Indonesia with successful and compliant track record.

This company was founded by Pak Budi, Pak Chan, Pak Freddy & Pak Agus. At present PT Wellesta CPI is led by Pak Freddy Hidajat as President Director. Indonesia is one of the fastest growing pharmaceutical markets in Asia and offers us good opportunity to partner with present MNCs in the country & companies who want to enter Indonesian market.

Our goal is to provide high quality professional services and support provide high quality healthcare products at optimum price to improve health to masses. We foresee this partnership will help accomplish our Vision and Mission through PT Wellesta CPI Healthcare in Indonesia. Our focus would be driven through our dedicated efforts, strong in-market experience, determination and veracity.
Abdul Latif Jameel Health and Wellesta announce collaboration to bring the innovative Butterfly iQ+TM Point-Of-Care Ultrasound (POCUS) solution to serve the medical imaging needs of over 1.3 billion people across India
Effective from 1st October 2022.


  • The Butterfly iQ+ is the only ultrasound transducer that can perform whole-body imaging in a single handheld probe using semiconductor technology to provide point-of-care ultrasound-driven insights.
  • Founded in 2020, Abdul Latif Jameel Health was created as a response to the ongoing global disparity in access to modern medical care, focusing on accelerating healthcare inclusion across the Global South.
Dubai UAE & Mumbai, India: October 19, 2022:
Abdul Latif Jameel Health, part of international diversified family business Abdul Latif Jameel, and Wellesta Holdings Pte. Ltd., a Singapore headquartered company providing marketing and commercialization support to the healthcare sector in South East Asia, India & partnering in MENA, today announced an important new agreement for the marketing and distribution of the Butterfly iQ+TM point-of-care ultrasound device in The Republic of India.

The innovative Butterfly iQ+TM1 is the world's first single probe, whole-body handheld point-of-care ultrasound solution. As part of its new agreement with Abdul Latif Jameel Health, Wellesta will register Butterfly iQ+TM in India and start promoting and selling the product in the country in the fourth quarter of 2022, bringing this technology to a potential 1.2 million registered physicians in the country2.

Today, more than 4.7 billion around the world lack access to medical imaging3 , from underserved communities in the United States to remote areas of Africa. The Butterfly iQ+TM aims to remedy this situation. Fusing semiconductors, artificial intelligence, and cloud technology, Butterfly has made it possible to usher in a new era of medical imaging and with it, healthcare.

This new collaboration will offer greater distribution of Butterfly iQ+TM to physicians in India thereby expanding the capabilities of the practitioners in making informed decisions thereby accelerating access to modern medical care for those who need it most.

Butterfly iQ+TM, is revolutionizing medical imaging. It is a hand-held 4 in 1 single probe whole-body innovative point-of-care ultrasound device powered by the world’s only Ultrasound–on-Chip™ technology.

This point of care device with over 20 default pre-sets is compatible with both iOS and Android smart devices and comes complete with battery back, wireless charging, cloud storage, customized app., software and AI support.

Hailed as potentially the ‘stethoscope of the future’, the Butterfly iQ+TM transforms what can sometimes be complex processes, into one connected and integrated point-of-care ultrasound (POCUS) system to help collect advanced imaging, perform rapid assessments, and guide critical procedures. It allows the sharing of results seamlessly with doctors across the globe to help read and interpret scans.

Speaking about this new collaboration, Mr. Milan Paleja, Chairman and Managing Director, Wellesta, said: “I am very excited to partner with Abdul Latif Jameel Health to market Butterfly iQ+TM in India to bring this breakthrough Ultrasound-on-ChipTM technology in the Butterfly probe to this market. Its versatile, innovative ultrasound solution will assist healthcare professionals to obtain point-of-care Ultrasound-driven insights - – across the vast country with a geographically disperse population to improve access to primary healthcare.”

Mr. Paleja added his thanks to deal advisor, Healthark Insights who supported this collaboration with Abdul Latif Jameel Health.

Akram Bouchenaki, Chief Executive Officer, Abdul Latif Jameel Health added: “Abdul Latif Jameel is addressing tangible real-world needs today, for a better tomorrow. We are focused on health care inclusion, accelerating access to modern medical care for those who need it most.

“We believe in realizing the true power of deep local knowledge, relationships, and partnerships to get the very best results for the communities we serve. In India, I am proud to collaborate with Wellesta who share our vision of improving live and lives across the Global South.”

[1] Butterfly iQ+TM is a Class IIa / Class B / Class II / Class II / IIa ultrasound system designed for diagnostic imaging by trained healthcare professionals. Carefully read and understand all cautions, warnings and operational instructions prior to use.

[2] In 2020, there were over 1.2 million doctors registered with the Indian Medical Council.

[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5704652/#R3
Note to Editors:

About Wellesta
Wellesta Holdings Pte Ltd is a healthcare company headquartered in Singapore with a direct market presence in Southeast Asia & India and partnering in MENA. We aim to serve clients and consumers through commercial and marketing support using an innovative approach across the Wellesta value chain. We work with companies to expand their presence in Southeast Asia & India as a strategic partner for companies present in these markets and act as a representative for companies that are not present in these markets and would like to sell/market their products in the region.

Wellesta Holdings operate in a spectrum of business verticals under our partner brands and own brands including pharmaceutical, nutraceuticals, OTC and medical devices, led by industry-proven leaders at HQ & Country level. Wellesta works as an extended arm for our principals through win-win partnership and provides superior quality products and services at the right price, by working at full compliance and transparency in our business approach. This joint collaboration supports the mission of Wellesta to provide cost-effective and high-quality products and services and help to deliver better patient outcomes in healthcare.

For further information, visit: www.wellesta.com and our LinkedIn page.

About Abdul Latif Jameel Health
Backed by Abdul Latif Jameel, one of the most respected diversified family businesses and investors with a 75-year heritage, deep roots, and established networks alongside a multi-sector presence in 30 countries across six continents, Abdul Latif Jameel Health is uniquely positioned as a trusted partner in realizing major innovations and opportunities in the healthcare world.

Abdul Latif Jameel Health reflects the Jameel family’s long-established commitment to innovating for a better future through Community Jameel, an international organization supporting science and technology-led solutions to global challenges. Community Jameel and MIT co-founded the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic) in September 2018 – which has rapidly become the very epicenter of AI and healthcare at MIT – and the Abdul Latif Jameel Institute for Disease and Emergency Analytics (Jameel Institute) co-founded with Imperial College London, in October 2019, using novel data analytics to reduce global risk of preventable disease most recently including the 2020 COVID-19 pandemic, and strengthening health systems in the most fragile settings.

Abdul Latif Jameel Health takes this commitment into the commercial environment addressing tangible real-world needs today, for a better tomorrow. It is focused on health care inclusion in the global south, accelerating access to modern medical care for those who need it most by opening up/growing new markets for distribution of existing solutions and investing in the future of MedTech.

The Jameel Investment Management Company (JIMCO) the global investment arm of the Jameel Family, actively invests in innovative, early-stage and breakthrough ventures and technology, aiming to positively shape the future of core industries driving the global economy through its’ investments that span medical and healthcare industries, from pharmaceuticals and vaccines to cutting-edge medical technology, along with emergent technologies across FinTech, InsurTech, electric vehicles and future mobility solutions.

For further information, visit: https://aljhealth.com and our brand video here.
Media Contact: Email aljhealth@edelman.com or telephone: +971 54 996 9935 (GMT +4 hours UAE)
For general inquiries: info@aljhealth.com
For adverse event reporting or medical enquiries: safety@aljhealth.com / T:+971 4 448 0905

Copyright Notice and Disclaimer
© Meddist Company Ltd. (Abdul Latif Jameel Health). All rights fully reserved. The Abdul Latif Jameel name, and the Abdul Latif Jameel logotype and pentagon-shaped graphic are trademarks, or registered trademarks of Abdul Latif Jameel IPR Company Limited.

The term “Abdul Latif Jameel” refers broadly to several distinct, separate and independent legal entities. Abdul Latif Jameel is not itself a corporate entity, association or conglomerate run by an overarching parent company but merely refers to a group of distinct and wholly separate legal entities that are collectively referred to as Abdul Latif Jameel. Abdul Latif Jameel is not a corporate group as defined in section 1161(5) of the Companies Act 2006.

This document may contain forward-looking statements. Forward-looking statements are statements regarding matters other than historical fact, such as future results, events, activities, developments or circumstances or the beliefs, plans or expectations of Abdul Latif Jameel Health or Abdul Latif Jameel entities or their respective management.

Forward-looking statements often can be identified by the use of words such as ‘expect’, ‘project’, ‘anticipate’, ‘plan’, ‘estimate’, ‘believe’, ‘predict’, ‘intend’, ‘potential’, ‘possible’, ‘probable’, ‘likely’, ‘forecast’, ‘guidance’, ‘outlook’, ‘goal’, ‘target’, ‘may’, ‘will’, ‘should’ or ‘could’ or other similar terms or phrases. However, the absence of such words does not mean that a particular statement is not forward looking.

Forward-looking statements are based on expectations and assumptions at the time of such statements and are subject to numerous risks and uncertainties, many of which are outside the control of Abdul Latif Jameel Health or Abdul Latif Jameel entities. Should any of such expectations or Further, any forward-looking statement speaks only as of the date on which it is made, and neither Abdul Latif Jameel Health nor Abdul Latif Jameel assumes, and hereby disclaims, any obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements made by Abdul Latif Jameel Health, Abdul Latif Jameel, or by any person on behalf of any of them, whether communicated in writing, electronically or orally, are qualified in their entirety by the foregoing cautionary statements.

No Offer or Solicitation
This communication is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

Important Note:
The Butterfly iQ+ product is not yet registered/marketed in all markets.
No News Found